--- title: "Pre-market hot trades in US stocks: Bitdeer Tech up 19.53% in pre-market; Cumberland Pharma down 8.22% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/294820521.md" description: "Bitdeer Tech pre-market rose 19.53%; Cumberland Pharma pre-market fell 8.22%; TNL Mediagene pre-market rose 115.58%; RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT) pre-market rose 88.01%; Ensysce Biosciences pre-market rose 59.51%" datetime: "2026-08-04T12:03:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294820521.md) - [en](https://longbridge.com/en/news/294820521.md) - [zh-HK](https://longbridge.com/zh-HK/news/294820521.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: Bitdeer Tech up 19.53% in pre-market; Cumberland Pharma down 8.22% in pre-market **Pre-market Hot Trades in US Stocks** Bitdeer Tech is up 19.53% in pre-market trading. Based on recent key news: 1. On August 1, Bitdeer announced that its Q2 2026 earnings call is scheduled for August 10, increasing market attention on its Bitcoin mining and AI cloud expansion, driving the stock price up. Source: Public Technologies 2. On August 1, Bitdeer deployed data centers in multiple countries worldwide, enhancing its AI infrastructure capabilities and boosting market confidence. Source: Public Technologies 3. On August 3, the upcoming earnings report from Bitdeer has attracted investor attention, with expectations to reveal the latest developments in Bitcoin mining and AI cloud business. Source: Public Technologies The focus on Bitcoin mining and AI cloud business has led to significant market volatility. Cumberland Pharma is down 8.22% in pre-market trading, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows notable volatility, and specific reasons need further observation. **Top Gainers in Pre-market US Stocks** TNL Mediagene is up 115.58% in pre-market trading. Based on recent key news: 1. On August 2, TNL Mediagene announced the launch of $500 million in convertible senior notes to support its commercialization efforts in the third quarter. This move demonstrates the company's ability to raise funds in the capital markets, significantly boosting the stock price. 2. On August 3, the market holds an optimistic view on TNL Mediagene's future development. Despite potential tightening in the macroeconomic environment, the company's self-financing capability in the high-margin software sector is considered one of its advantages, further lifting the stock price. 3. On August 4, TNL Mediagene's press conference highlighted its strategic adjustments in the digital media sector, enhancing market confidence in its future growth potential, and the stock price continued to rise. The digital media industry faces challenges with capital costs. RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT) is up 88.01% in pre-market trading, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows notable volatility, and specific reasons need further observation. Ensysce Biosciences is up 59.51% in pre-market trading. Based on recent key news: 1. On August 4, Ensysce Biosciences announced significant progress in its new drug development, with a positive market reaction, leading to a substantial increase in stock price. The company stated that its new drug has shown significant efficacy in clinical trials and is expected to enter the next phase of testing soon, driving the stock price up 59.51% in pre-market trading; 2. On August 3rd, Ensysce Biosciences received an important patent authorization, further consolidating its competitive advantage in the biopharmaceutical field. After the announcement of the patent authorization, investor confidence increased, and the stock price continued to rise; 3. On August 2nd, analysts upgraded Ensysce Biosciences' rating, expecting the company's future performance to improve significantly. Analysts pointed out that the company's investment in research and development and marketing will bring long-term benefits, driving the stock price up. The biopharmaceutical industry has performed strongly recently, attracting high investor attention ### Related Stocks - [BTDR.US](https://longbridge.com/en/quote/BTDR.US.md) - [CPIX.US](https://longbridge.com/en/quote/CPIX.US.md) - [TNMG.US](https://longbridge.com/en/quote/TNMG.US.md) - [RDACR.US](https://longbridge.com/en/quote/RDACR.US.md) - [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md) ## Related News & Research - [Bitdeer Ai Targets 350Mw Ai Cloud Data Center Capacity By Q1 2028](https://longbridge.com/en/news/296362972.md) - [A mysterious free AI model is impressing developers. And nobody knows who made it.](https://longbridge.com/en/news/296687985.md) - [QUICK SPARK: AI Does the Stock-Picking in this New ETF](https://longbridge.com/en/news/296653331.md) - [Why Wolfe Research Just Named Nvidia Stock Its Top AI Pick](https://longbridge.com/en/news/296822517.md) - [Consulting's race to become AI native](https://longbridge.com/en/news/296676838.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**